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Quality of life and acquired organ damage
are intimately related to activity limitations in
patients with systemic lupus erythematosus
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Abstract
Background: Systemic lupus erythematosus (SLE) is an autoimmune multi-organ disease, characterized by episodes
of disease flares and remissions over time, which may restrain affected patients’ ability to perform daily activities.
The purpose of the present study was to characterize variation in activity limitations among well-defined SLE
patients, and to describe disease phenotypes, acquired organ damage and their relations to activity limitation and
self-reported health, respectively.
Methods: The disease phenotypes were organized into 4 different clinical groups and logistic regression analyses
were used to identify how an elevated health assessment questionnaire (HAQ) score was related to disease
variables such as phenotypes, disease activity and damage accrual. Correlation and multiple linear regression
analyses were used to examine the association between each group of variables – background variables, disease
variables and self-reported measurements – and the degree of elevated HAQ.
Results: We found a higher proportion of activity limitation in patients with skin and joint involvement compared
to others. The presence of activity limitation, as detected by the HAQ instrument, was significantly associated with
quality of life (EuroQol–5D) and accrual of organ damage using the Systemic Lupus International Collaborative
Clinics/ACR damage index.
Conclusions: The findings highlight the differing requirements of the multi-professional rehabilitation interventions
for the various SLE phenotypes in order to optimize the clinical care of the patients.
Keywords: Systemic lupus erythematosus, Disease burden, Organ damage, Disability, Quality of life, Activity
limitation, Disease phenotype
Background
Systemic lupus erythematosus (SLE) is a chronic inflam-
matory condition characterized by multiple organ in-
volvement, production of antibodies against nuclear
constituents and deposition/formation of immune com-
plexes in the affected organs [1]. The clinical spectrum
of various disease phenotypes is remarkably diverse and
this constitutes a challenge, both in terms of clinical as-
sessment, pharmacological and non-pharmacological
treatment. This is furthermore of major concern since
periods of uncontrolled disease as well as medical side-
effects over time may result in irreversible organ damage
[2]. The current treatment strategies with glucocorti-
coids and disease-modifying anti-rheumatic drugs
(DMARDs) intend to relieve symptoms, induce remis-
sion, or at least allay the disease activity, prevent future
flares and subsequent damage accrual [3].
SLE often affects relatively young patients who are in
their most productive years of life [4], and consequences
such as disability including work loss [5], activity limita-
tions [6, 7], perceived mental and physical exhaustion
[8] and reduced quality of life (QoL) [9–11] are com-
monly found. Although new treatment options for SLE
have recently become available [12], patients continue to
report disability. Previous studies report that associations
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between perceived QoL and disease activity or disease
severity are not clear-cut [13–16]. Instead, many authors
conclude that the disease burden in SLE is multi-
dimensional and has important physical as well as men-
tal aspects [11, 13, 17, 18].
To be able to optimize the rehabilitation efforts for
SLE patients, the knowledge about what is related to
activity limitations and self-reported health needs to be
expanded. Despite that more than 60 % of the patients
with SLE have either periodically or permanently re-
duced ability to perform daily activities [19], it has to
our knowledge not been studied whether activity limita-
tions and disease manifestations are related or not. An
early study by Milligan et al. [20] displayed that activity
limitations as measured by the health assessment ques-
tionnaire (HAQ) were not related to disease activity in
female SLE patients, which could possibly be con-
founded by HAQ being more related to other aspects
of disability [6], and/or confounders in self-reporting. A
reduced health-related quality of life (HRQL) assess-
ment in SLE patients, on the other hand, was shown to
be associated with musculoskeletal impairments [21].
These findings imply that disability and self-reported
health in SLE may be better explained by measures other
than global disease activity, e.g., acquired organ damage,
number of involved organ systems or disease phenotype.
Thus, the aims herein were to characterize variation in
activity limitations among well-defined SLE patients, and
to describe disease phenotypes, acquired organ damage
and their relations to activity limitation and self-
reported health, respectively.
Methods
Patients & laboratory analyses
In total, 192 SLE patients included in a prospective pro-
ject with structured follow-up at the Rheumatology
clinic, Linköping university hospital, Sweden, were in-
cluded in the present cross-sectional study. The study
was based on data from the most recent visit to the
rheumatologist during 2011. The patients were recruited
consecutively without regard taken to present disease
activity. Most were prevalent cases (93 %), but some
(7 %) had newly diagnosed SLE at the time-point of data
collection. One hundred and fifty four patients (80 %)
fulfilled the 1982 ACR classification criteria [22],
whereas 38 (20 %) had a clinical diagnosis of SLE based
on a history of abnormal antinuclear antibody (ANA)
titre by immunofluorescence microscopy plus at least
two typical organ manifestations (referred to as the Fries’
diagnostic principle) [23]. One hundred and seventy
patients (89 %) fulfilled the 2012 Systemic Lupus Inter-
national Collaborative Clinics classification criteria [24].
The study population has recently been described in
detail [25].
Laboratory analyses included erythrocyte, leukocyte and
platelet counts, urinalysis, erythrocyte sedimentation rate
(ESR), high sensitivity C-reactive protein (CRP), creatine
kinase, creatinine and plasma complement proteins (C3,
C4). IgG class antibodies with reactivity against double-
stranded (ds) DNA were detected by the Crithidia luciliae
microscopy test; 56/192 (29 %) individuals were positive at
the time-point of data collection, whereas altogether 44 %
had been anti-dsDNA antibody positive at least once (cut-
off titre of 1:10, corresponding to >99th percentile among
healthy female blood donors was used) [26].
Primary outcome measure
The validated Swedish version of HAQ [27] measuring
self-reported activity limitation was the primary out-
come. The HAQ consists of 20 questions representing
common daily activities. The response alternatives for
each of the 20 questions were ‘without any difficulty’
(score = 0), ‘with some difficulty’ (score = 1), ‘with much
difficulty’ or ‘with use of an assistive device’ (score = 2),
and ‘unable to do’ (score = 3). The highest score ob-
tained for any question of a given subcategory deter-
mines the score for the subcategory. A total score (0–3)
was calculated based on the sum of the scores for the
various subcategories divided by the number of subcat-
egories that were answered. The Swedish version of
HAQ is well-established psychometrically tested with
good results [28] and widely used also in SLE [6, 29].
Background variables
Background variables concerning age, sex and disease
duration were collected. The use of anti-rheumatic
drugs, including antimalarials, other DMARDs and glu-
cocorticoids was registered.
Disease variables
The number of fulfilled American Collegue of Rheumatol-
ogy (ACR) criteria was registered and the study population
was organized into different disease phenotypes based on
the 1982 ACR classification criteria (i.e., skin disease, arth-
ritis, renal or hematologic disorders) [22]. Acquired organ
damage was estimated using the validated Systemic Lupus
International Collaborative Clinics/ACR damage index
(SDI), which covers 12 organ systems and measures accu-
mulated organ damage that has occurred since the onset
of SLE. SDI is scored regardless of whether the damage
can be attributed to SLE or to other causes [2, 30]. Disease
activity was recorded by the SLE disease activity index
2000 (SLEDAI-2 K), both with and without index modifi-
cation by the exclusion of laboratory items for hypocom-
plementemia and anti-dsDNA antibody binding [31].
In addition, the physician’s global assessment (PGA;
scored 0 = remission and to 4 =maximum disease activity)
of perceived disease activity was registered [32].
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Self-reported measures
Four patient self-reported measures were used to capture
a wide range of disability and health; pain intensity, activ-
ity limitation, QoL and well-being. Pain intensity, defined
as ‘the experienced pain because of your SLE during the
last week’, was self-reported on a 0–100 mm visual
analogue scale (VAS) ranging from 0 (no pain at all) to
100 (worst possible pain). Wellbeing was estimated in the
same manner, with 0 representing ‘best possible wellbeing’
and 100 ‘worst possible wellbeing’ [33]. Generic HRQL
was measured using EuroQol–5D (EQ5D) that provides a
profile of the self-reported problems based on five differ-
ent dimensions [34]. EQ5D is useful and reliable to predict
HRQL in different conditions [35].
Statistical analysis
Disease phenotypes were organized into 4 different clin-
ical groups; skin disease (ACR criteria No. 1–3), arthritis
(ACR criterion No. 5), renal disorder (ACR criterion No.
7) and hematologic disorder (ACR criterion No. 9) [22].
Differences in proportions between patients with activity
limitation (HAQ > 0) and patients without activity limi-
tation (HAQ = 0) were examined by Chi-square tests of
proportions and differences in levels between the two
groups were examined by Mann–Whitney U tests.
Associations between the variables and HAQ were ex-
amined in a two-step procedure: (1) examination of vari-
ables associated with elevated HAQ score (1 = elevated
HAQ, 0 = no elevated HAQ), and (2) examination of
variables associated with degree of elevated HAQ given
that patients have elevated HAQ.
Step 1: Correlations were examined between elevated
HAQ and each group of variables (background variables,
disease variables and self-reported measures). To further
examine the overall association between elevated HAQ
and all groups of variables (background variables, disease
variables and self-reported measures) the variables that
correlated significantly with elevated HAQ were used in
multiple logistic regression analyses, first for each group
of variables and thereafter for all variables (using a step-
wise forward procedure where at each step the variable
which added most to the model was added until no more
variable could be added with p < 0.05).
Step 2: Given an elevated HAQ, correlations were then
examined between degree of activity limitation and each
group of variables (background variables, disease vari-
ables and self-reported measures). To further explore
combined correlations (i.e., shared variance) between the
variables and degree of elevated HAQ, variables that cor-
related significantly with elevated HAQ were put into
multiple linear regression analyses (using a stepwise for-
ward procedure where at each step the variable which
added most to the model was added until no more vari-
able could be added with p < 0.05).
All analyses were done using IBM SPSS version 20.0.
P-values < 0.05 were considered significant.
Ethics and consent
Oral and written informed consent was obtained from
all subjects and the patient anonymity has been pre-
served. The study protocol was approved by the regional
ethical review board in Linköping (Decision No. M75–
08/2008).
Results
The study population consisted of 192 patients,
whereof 172 were women (mean age, 52.3 years; range,
18–87) and 20 were men (mean age, 56.0 years; range,
27–90). Data on background variables, disease variables
and self-reported measures for all patients are given in
Table 1. The distribution of acquired organ damage
(SDI) in the study population is shown in Figure 1.
The group that reported any difficulty in performing
daily activities (HAQ > 0) consisted of 117 patients
(61 %). This group was significantly older, used glucocor-
ticoids to a higher extent, had more damage accrual and
frequently fulfilled the ACR classification criteria for dis-
coid rash. However, the group with elevated HAQ had
less of the hematologic phenotype compared to the
group where the HAQ score was zero (Table 1). In
addition, the group with difficulties in performing daily
activities reported significantly more pain, but lower
QoL and well-being (Table 1). The distribution of pa-
tients with different phenotypes and/or elevated vs. no
elevated HAQ scores is shown in Fig. 2; observe the high
frequency of patients (n = 38) characterized by skin/joint
involvement, without renal/hematologic phenotype, and
elevated HAQ scores. Patients meeting ACR criteria for
hematologic disorder had less of the arthritic phenotype
(p =0 .003, Cramer’s V = 0.21), and patients without dif-
ficulties in performing daily activities were more often
associated with the hematologic phenotype (p = 0.002,
Cramer’s V = 0.22).
Using the results from distributions of cases accord-
ing to phenotype and elevated HAQ scores, only the
absence of hematologic phenotype was found to be sig-
nificantly related to elevated HAQ in the logistic re-
gression (Table 2). In background variables, age was
significantly associated with elevated HAQ score, and
among the disease variables this was also the case for
SDI. In the self-reported measures, both EQ5D and
well-being were significantly correlated with elevated
HAQ. Finally, variables that correlated significantly
with elevated HAQ, were merged into a final logistic
regression analysis (Table 2) showing a Hosmer &
Lemeshow R2 as well as a Cox & Snell R2 of 0.41.
Among the patients with activity limitation, a multiple
linear regression with the variables that were significantly
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correlated with HAQ explained 50 % of the variance in
HAQ scores. As demonstrated in Table 3, given an eleva-
tion of HAQ, EQ5D was identified to have the strongest
relation to HAQ, followed by SDI. Even though age, pain
and well-being significantly correlated with degree of ele-
vated HAQ, these variables could not add any significant
explanation of variance in HAQ elevation than to what
could be explained by EQ5D and SDI. Repeated analyses
excluding patients with lowest HAQ elevation (to control
for somewhat positively skewed data) yielded similar
results.
Discussion
Activity limitations in the daily life constitute major
problems for individuals with SLE [13]. This cross-
sectional cohort study of 192 well-characterized patients
Table 1 Patient characteristics. Characteristics of the patients in relation to the presence of activity limitations
Characteristics Mean (standard deviation) [range], or % p-value***
Total (n = 192) HAQ > 0 (n = 117) HAQ = 0 (n = 75)
Background variables
Age (years) 52.7 (17.4) [18–90] 56.8 (17.1) [18–90] 46.2 (16.0) [21–87] <0.0001
Females 89.6 % 90.6 % 88.0 % n.s.
Caucasian ethnicity 92.5 % 92.9 92.0 n.s.
Disease duration (years) 13.4 (10.2) [0–48] 14.3 (11.3) [0–48] 12.0 (8.2) [0–38] n.s.
Continuous medication
AM as only DMARD 40.6 % 41.0 % 40.0 % n.s.
Other DMARD ± AM 29.7 % 30.8 % 28.0 % n.s.
Glucocorticoids 58.9 % 70.9 % 40.0 % <0.0001
Disease variables
Fulfilled ACR criteria (n) 4.6 (0.3) [3–9] 4.5 (1.2) [3–8] 4.7 (1.4) [3–9] n.s.
1. Malar rash 43.2 % 47.0 % 37.3 % n.s.
2. Discoid rash 16.1 % 20.5 % 9.3 % 0.04
3. Photosensitivity 52.6 % 54.7 % 49.3 % n.s.
4. Oral ulcers 9.4 % 9.4 % 9.3 % n.s.
5. Arthritis 76.6 % 76.9 % 76.0 % n.s.
6. Serositis 39.1 % 36.8 % 42.7 % n.s.
7. Renal disorder 20.8 % 17.1 % 26.7 % n.s.
8. Neurologic disorder 4.2 % 4.3 % 4.0 % n.s.
9. Hematologic disorder 51.6 % 42.7 % 65.3 % 0.002
10. Immunologic disorder 46.9 % 44.4 % 50.1 % n.s.
11. Antinuclear antibody* 98.4 % 97.4 % 100 % n.s.
SDI 1.4 (1.9) [0–8] 1.9 (2.1) [0–7] 0.79 (1.39) [0–8] 0.0001
SLEDAI-2 K 2.3 (3.3) [0–24] 2.3 (3.7) [0–24] 2.3 (2.7) [0–11] n.s.
Modified SLEDAI** 1.0 (2.5) [0–20] 1.2 (2.9) [0–20] 0.81 (1.96) [0–10] n.s.
Physician’s global assessment (PGA) 0.26 (0.55) [0–3] 0.29 (0.62) [0–3] 0.20 (0.43) [0–2] n.s.
Self-reported measures
Pain intensity (mm) 29.0 (27.1) [0–100] 38.5 (27.0) [0–100] 13.0 (18.5) [0–73.2] <0.0001
HAQ (0–3)**** 0.44 (0.60) [0–3.0] 0.73 (0.62) [0.13–3.0] 0
EQ5D 0.67 (0.30) [−0.35–1] 0.56 (0.31) [−0.35–1] 0.84 (0.18) [0–1] <0.0001
Well-being (mm) 29.8 (25.8) [0–100] 39.2 (24.7) [0–100] 13.6 (18.8) [0–74.2] <0.0001
*Abnormal titre of ANA by immunofluorescence microscopy
**SLEDAI–2 K indicated by the exclusion of laboratory items for hypocomplementemia and anti-dsDNA antibody binding
***Performed with Mann–Whitney U test or Chi-square test (where appropriate)
****Primary outcome measure
AM = Antimalarials; DMARD = disease modifying anti-rheumatic drugs; SDI = Systemic Lupus International Collaborative Clinics/ACR damage index; SLEDAI = SLE
disease activity index–2 K; HAQ = Health Assessment Questionnaire
EQ5D = EuroQol–5D; n.s. = not significant
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provides evidence for a higher proportion of activity
limitation in SLE patients with skin and joint involve-
ment compared to others. In addition, we found that the
presence of activity limitation as detected by the HAQ
instrument was significantly related to QoL (EQ5D) and
acquired organ damage (SDI). Since previous research
has, to our knowledge, not been focusing on the relation
between organ damage and self-reported aspects in well-
defined and established SLE our findings are novel. SLE
patients have reported different types of discomfort re-
lated to involvement of organs and also their body to be
unpredictable in how their daily activities and health are
affected by the disease [36]. Our findings add knowledge
to the relation between the different phenotypes of the
disease and the experience of SLE in daily life. This un-
derlines the different requirements of the multi-
professional rehabilitation interventions for the various
SLE phenotypes in order to optimize the clinical care of
the patients.
Although the HAQ instrument was originally devel-
oped for rheumatoid arthritis (RA) [37], it has also
been employed for SLE [6, 16, 17, 20, 29], and repre-
sents a useful measure of activity limitation in dispar-
ate rheumatic conditions [27, 38–40]. In our study
population the overall mean of HAQ was 0.44, this is
in line with previous results on disability in SLE [6, 29]
and significantly altered in relation to HAQ in the
Swedish general population (HAQ score of 0.08) [41].
In the study by Malcus Johnsson et al. [6], 42 % of the
patients reported interference with performance of
daily activities (HAQ > 0) whereas we found a slightly
higher proportion of patients with activity limitations
(61 %). The sample in the present study was obviously
older (but had similar disease duration), and this could
possibly explain some of the difference. Our observa-
tion of a distinct relative increase of raised HAQ scores
in individuals with skin and joint involvement is not
surprising, since this lupus variant may resemble RA in
many ways. Gilboe et al. used the modified HAQ instru-
ment (MHAQ) [42] and found that activity limitations
in Norwegian SLE patients were stable over time and
did not predict future organ damage as was assessed by
the SDI [17, 43].
Fig. 1 Distribution of organ damage. The figure illustrates the
distribution of damage accrual for each domain according to the
Systemic Lupus International Collaborative Clinics/ACR damage
index. Of the 192 included patients, 106 (55 %) showed acquired
organ damage in at least one organ domain
Fig. 2 Disease phenotype vs. activity limitation. Distribution of patients reporting activity limitation (HAQ) in the different clinical groups. Patients
were divided with regard to disease phenotypes (ACR-82 criteria No. 1–3 = skin disease; No. 5 = arthritis; No. 7 = renal disorder; and No.
9 = hematologic disorder). The graph should be read as, for example, in the lower right panel patients with renal and skin disease are further
categorized into arthritis and/or hematologic manifestations. * actual value for HAQ > 0 is 38
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Difficulties in performing daily activities have, to our
knowledge, not been reported in SLE patients with
mainly skin manifestations. However, Goreshi et al. [44]
reported that 62 % of patients with dermatomyositis had
an elevated HAQ score which was also associated with
reduced QoL. Thus, based on results from these authors
as well as from the present study, patients with skin dis-
ease may be underserved in terms of being evaluated by
clinicians for activity limitations and self-reported health.
In order to evaluate the need for rehabilitation interven-
tions by for example by occupational therapist and phys-
ical therapists, HAQ could be used as a part of the
clinical routine for patients with skin manifestations.
In the present study, organ damage (SDI), age, QoL
(EQ5D) and well-being were significantly correlated with
elevation of HAQ score. Among the disease phenotypes,
the absence of hematologic disorder had the strongest as-
sociation with a raised HAQ score. Given that the HAQ
instrument is known to cover different aspects of arthritis,
and that the hematologic and arthritic phenotypes were
inversely associated herein, it could be speculated that it is
the presence of arthritis per se, rather than the absence of
hematologic disorder, which promotes this significance.
Table 2 Activity limitation predictors. Multiple logistic regression models of the effect of clinical measures on the risk of elevated
HAQ score among individuals with SLE
95 % CI for Odds Ratio R2 Predictive ability
B (SE) P LL OR UL H&L C&S Sens. Spec.
Phenotypes 0.04 0.05 1 0
Constant 0.947 (0.231)
Hematologic −0.926 (0.306) 0.002 0.217 0.396 0.722
Background variables 0.07 0.09 0.79 0.45
Constant −1.49
Age 0.037 (0.009) <0.001 1.019 1.038 1.057
Disease variables 0.06 0.08 0.66 0.60
Constant −0.006 (0.191)
SDI 0.375 (0.108) <0.001 1.178 1.455 1.798
Self-reported measures 0.26 0.29 0.84 0.76
Constant 1.891 (1.318)
EQ5D −3.276 (1.502) 0.029 0.002 0.038 0.717
Well-being 0.043 (0.014) 0.001 1.017 1.044 1.072
Overall 0.41 0.41 0.87 0.69
Constant 0.817 (1.434)
Age 0.031 (0.016) 0.050 0.941 0.970 1.000
SDI 0.432 (0.194) .0026 1.053 1.541 2.256
EQ5D −3.350 (1.502) 0.026 0.002 0.035 0.666
Well-being 0.048 (0.014) <0.001 1.020 1.049 1.078
Hematologic −1.709 (0.532) 0.001 0.064 0.181 0.513
LL = lower limit; UL = upper limit; H&L = Hosmer & Lemeshow; C&S = Cox & Snell; Sens. = sensitivity; Spec. = specificity; SDI = Systemic Lupus International
Collaborative Clinics/ACR damage index; EQ5D = EuroQol–5D
Table 3 Predictors of HAQ. Factors predicting impaired high
scores of HAQ among patients with elevated HAQ (Multiple
Linear Regression Analysis); n = 117)
B SE B BETA P R
Step 1
Constant 1.444 0.091
EQ5D −1.285 0.143 −0.642 <0.001 −0.64
Step 2
Constant 1.132 0.106
SDI 0.099 0.021 0.334 <0.001 0.52





Note: R2 = 0.41 for Step 1, ΔR2 = 0.10 for Step 2 (p < 0.001)
B is the regression coefficient, SE B the standard error of B, BETA is the
standardized regression coefficient
r = Pearson correlation between independent variables and HAQ scores
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The HAQ instrument has previously been shown to be
strongly associated with well-being and QoL in SLE
[6, 38], as well as in other rheumatic diseases [41], which
is probably a sign of self-reported measures being closely
related in rheumatic diseases [45]. This is seen in our re-
sults by EQ5D being highly associated with risk of elevated
HAQ. In RA, however, HAQ is only weakly related to dis-
ease variables, such as the DAS28 score [41]. In line with
the observation of Milligan et al., [20] we found no associ-
ation between disease activity and activity limitations. In
fact, SDI was the only disease variable that significantly ex-
plained variance in degree of HAQ elevation (given ele-
vated HAQ). Whereas it is rather easy to capture subtle
signs of irreversible organ damage leading to activity limi-
tations in RA by longitudinal radiographic examinations
[46], the challenge is greater in SLE. SDI measures the ac-
cumulated organ damage in several organ systems that
has occurred since the onset of SLE and has been present
for at least 6 months regardless of its cause (i.e., caused by
disease flares, therapeutic side-effects or concomitant dis-
eases) [30]. Several studies have shown a convincing cor-
relation between SDI and disease outcome, particularly if
damage occurs early [47–49]. Thus, SDI covers a broad
spectrum of symptoms and sequelae that potentially can
have major impacts on the ability to perform daily activ-
ities; therefore it is not unexpected that SDI is closely as-
sociated with HAQ. In addition, increased damage accrual
was recently identified to be an important predictor of the
total cost for SLE care in Sweden [50]. However, this study
did not have the statistical power to consider which types
of damage that were specifically associated with an elevated
HAQ score. The individual SDI items have a wide range of
variability, some of which are expected to affect HAQ (e.g.,
deforming arthritis, osteoporosis, osteonecrosis), whereas
others are not expected to affect HAQ in the majority (e.g.,
renal, diabetes and premature gonadal failure).
Related to the finding of age as being significantly related
to elevated HAQ score in SLE patients, Poole et al. [51] re-
cently found activity limitation to be pronounced in youn-
ger parenting females with SLE. Mothers with small
children (<5 years) reported that having energy to talk/lis-
ten to a child was the most difficult parenting task. Mothers
with children older than 5 years of age reported difficulties
in playing games, shopping, and doing household chores.
A limitation with the HAQ instrument is that it includes
only predefined activities focusing on self-care and basic
needs. More recently, however, the need for incorporation
of the patient perspective in assessment and interventions
has been stressed [52] and assessments of a broader range
of functioning, including measures of participation has
been used [53, 54]. As an extension of the present study
these measures could be used to for example capture the
activity limitations and preferences expressed by younger
women with SLE.
The large Swedish study population with well-organized
data and very few internal missing values constitute the
strengths of this study. However, although several import-
ant conclusions were drawn it also has limitations. In the
comparison of patients with an elevated HAQ score and
the patients with an unaffected HAQ, the patients with
elevation in HAQ had a higher extent of organ damage,
were prescribed higher doses of glucocorticoids and were
older. Age has earlier been reported to have an impact on
HAQ [55], and thus it cannot be excluded that age rather
than SLE per se account for some of the differences in ac-
tivity limitation between the two groups. Even though
HAQ is not psychometrically tested in SLE it is well estab-
lished and used in earlier research and also recommended
as an outcome measure in SLE [56]. The study with a
cross-sectional design, within a more comprehensive pro-
spective project, did not evaluate changes in a longitudinal
perspective. To fully explore the relationship between
background variables, disease variables and self-reported
measures, we warrant future studies monitoring the
changes in self-reported measures as disease variables
changes over time. Also fatigue and depressive symptoms,
as self-reported aspects often altered by SLE should be in-
cluded to cover a wider range of disability.
Conclusions
In conclusion, EQ5D and the SDI were shown to have the
strongest associations with activity limitations in this
Swedish SLE population. These instruments record two
completely different aspects of the disease, and this clearly
illustrates the complexity of activity limitations in SLE.
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